Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity.Walker, D.P., Zawistoski, M.P., McGlynn, M.A., Li, J.C., Kung, D.W., Bonnette, P.C., Baumann, A., Buckbinder, L., Houser, J.A., Boer, J., Mistry, A., Han, S., Xing, L., Guzman-Perez, A.
(2009) Bioorg Med Chem Lett 19: 3253-3258
- PubMed: 19428251
- DOI: https://doi.org/10.1016/j.bmcl.2009.04.093
- Primary Citation of Related Structures:
- PubMed Abstract:
The synthesis, in vitro properties, and in vivo pharmacokinetics for a series of sulfoximine-substituted trifluoromethylpyrimidines as inhibitors of proline-rich tyrosine kinase, a target for the possible treatment of osteoporosis, are described. These compounds were prepared as surrogates of the corresponding sulfone compound 1. Sulfone 1 was an attractive PYK2 lead compound; however, subsequent studies determined this compound possessed high dofetilide binding, which is an early indicator of cardiovascular safety. Surprisingly, the corresponding sulfoximine analogs displayed significantly lower dofetilide binding, which, for N-methylsulfoximine (S)-14a, translated to lower activity in a patch clamp hERG K(+) ion channel screen. In addition, compound (S)-14a shows good oral exposure in a rat pharmacokinetic model.
Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. email@example.com